Oxygen/ozone as a medical gas mixture. A critical evaluation of the various methods clarifies positive and negative aspects by Velio Bocci et al.
REVIEW Open Access
Oxygen/ozone as a medical gas mixture. A critical
evaluation of the various methods clarifies
positive and negative aspects
Velio Bocci1*, Iacopo Zanardi2 and Valter Travagli2*
Abstract
Besides oxygen, several other gases such as NO, CO, H2, H2S, Xe and O3 have come to age over the past few years.
With regards to O3, its mechanisms of action in medicine have been clarified during the last two decades so that
now a comprehensive framework for understanding and recommending ozone therapy in various pathologies is
available. O3 used within the determined therapeutic window is absolutely safe and more effective than golden
standard medications in numerous pathologies, like vascular diseases. However, ozone therapy is mostly in
practitioners’ hands and some recent developments for increasing cost effectiveness and speed of treatment are
neither standardized, nor evaluated toxicologically. Hence, the aim of this article is to emphasize the need to
objectively assess the pros and cons of oxygen/ozone as a medical gas mixture in the hope that ozone therapy
will be accepted by orthodox medicine in the near future.
Introduction
Two decades ago it would have appeared paradoxical to
suggest the use of some gases for therapeutic purposes,
but today there is an ample literature indicating the
importance of NO [1-3], CO [1,3-6], CO2[7], H2S
[1,3,6,8], H2[1,9], Xe [1,10], and O3[11-13]. Oxygen,
although it is essential for aerobic organisms for respira-
tion as well as energy production, has been therapeuti-
cally used for a long time [14]. It also can be either
toxic or lethal for humans if it is continuously inhaled
pure for about 60 hours [15]. In the 16th century Para-
celsus had already expressed the concept that “the dose
makes the poison”. Indeed, minimal concentration of
NO, CO and H2S are of crucial importance in physiolo-
gical conditions, but they become detrimental at high
doses. Although the transient presence of an ozone-like
compound has been postulated in atherosclerotic pla-
ques [16,17], it has no role in normal conditions. Ozone
is one of the most controversial gases because it is use-
ful in the stratosphere for blocking UV radiations but
toxic in the troposphere during chronic air inhalation.
This is because in humans the great expanse of the
alveolar surface (about 70 m2) is protected only by a
scanty volume (about 25 mL) of lining fluid which, by
having a small antioxidant content, cannot quench the
strong oxidant activity of ozone. The opposite is true for
blood because both the plasma and blood cells have a
remarkable quantity of mutually cooperating antioxi-
dants. Against the old concept that ozone is always
toxic and it should not be used in medicine, a compara-
tive analysis between the lungs vs. blood has fully clari-
fied the possibility of using ozone as a therapeutic agent
provided that dosages are not overwhelming the blood
antioxidant capacity [18].
The aim of this article is to clarify the state-of-the-art
therapeutic use of the oxygen/ozone mixture. The versa-
tility of ozone application is impressive because if prop-
erly used it can be proficient in vascular diseases
(chronic limb ischemia, diabetic foot, heart infarction
and stroke) and surprisingly in orthopedics and odon-
toiatry [19]. In infection diseases (bacterial, viral, fungal),
it can only support antibiotics and/or chemotherapy
because ozone cannot ever destroy bacteria or viruses in
blood and cells where disappointingly these pathogens
are well protected by the endogenous antioxidant system
[20]. On the other hand, ozone either as a gas or
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dissolved in pure water can be an excellent disinfectant
for cutaneous and mucosal infections. Nonetheless, it
has become clear that well-developed countries neglect
or ostracize the use of ozone in medicine because of the
ample availability of drugs and the power of pharmaceu-
tical firms. On the other hand, in less-developed coun-
tries in places such as South America and Eastern
Europe (mainly Russia and Ukraine), expensive drugs
are less available and there is a growing tendency to use
ozone as a sort of panacea. Owing to the vast number
of patients, a worrying trend is the invention of cheap
and rapid ozone treatments which are based on
approaches which may be either unsafe or ineffective.
Apart from the use of topical ozone derivatives in der-
matology [21,22], such a concern may get even worse
because some practitioners and naturopaths, lacking
on appropriate chemical and biological skills, do not
understand the toxic risk of unstable solutions, possibly
containing excessive amounts of ozone. There are many
commercially available medical ozone generators able to
monitor the production of ozone as a gas, thus deter-
mining the ozone concentration. Any interested reader
must be careful on the quality of both equipment mate-
rials and measurement devices, mainly in terms of
ozone-resistance and accuracy, respectively.
A) Mechanism of action of ozone in blood
These aspects have been extensively discussed elsewhere
[11,23] and they need to be summarized as follows.
Owing to the potent antioxidant capacity of blood due
to its hydrophilic, lipophilic antioxidants and cellular
enzymes, some of the ozone dose dissolved in the water
of plasma is instantly quenched by free antioxidants
(mainly uric acid, ascorbic acid, reduced glutathione -
GSH, cysteine and albumin), while the remaining ozone
reacts with polyunsaturated fatty acid (PUFA) mostly
present in the three hydrophobic tasks of albumin [24].
-R-CH=CH-R + H2O + O3  2RCHO + H2O2
Thus, the potential energy of ozone is finally trans-
ferred into two fundamental messengers such as H2O2
as a reactive oxygen species (ROS) and aldehydic mole-
cules of which 4-hydroxynonenal (4-HNE) and trans-4-
hydroxyhexenal (4-HHE) are the relevant lipid oxidation
products (LOP):
Plasmatic water + O3  H2O2 + 4-HNE + HHE
Due to the high ozone reactivity, these biochemical
reactions occur in a few seconds and in fact, within the
canonical five minutes of mixing an average 200 mL of
human blood ex vivo in a sterile glass bottle with the
200 mL corresponding volume of the gas mixture (O2
+O3), ozone is totally exhausted while about 95%
oxygen, dissolved in the plasma water, fully saturates
hemoglobin.
Blood oxygenation goes up to about 400 mm Hg in
the bottle is useful, but it has only a little practical rele-
vance because oxygenated-ozonated blood is normally
reinfused via venous route into the donor during the
next 20 minutes and is abundantly diluted with venous
blood. Therefore ozone represents the medical drug
while pure oxygen is only necessary for generating
ozone.
During the initial fast and multiple reactions of ozone
with the plasmatic components, a variable amount of
the ozone dose is neutralized by the wealth of the
hydrophilic antioxidants. It is noteworthy that, with the
exception of uric acid oxidized to allantoin, dehydroas-
corbate and GSH disulfide are reduced back to their
normal value in less than twenty minutes due to the
exceptional efficiency of the recycling system based on a
multitude of reducing molecules such as alpha-lipoate,
Vitamin E, thioredoxin, and last but not least NADPH
[25,26] acting in a well-coordinated sequence of electron
donations [27].
Most importantly, H2O2, being unionized, rapidly
enters into all blood cells and the chemical gradient
between plasma-cells has been measured to be about
10% of the extracellular concentration [28-30]. In other
words, when the highest ozone concentration is mixed
with blood, depending upon the interindividual variabil-
ity of antioxidant potency (1.28-1.83 mmol/L plasma)
[31], the highest H2O2 concentration measured in
plasma is about 40 μM [32] and therefore inside the
cells is at most 4 μM. This sudden inflow of this small
amount of H2O2 inside blood cells is the indispensable
stimulus to activate a series of biochemical reactions as
follows:
i) in the erythrocytes: activation of glycolysis with
increase of ATP and 2,3-diphosphoglycerate. Function-
ally, the oxyhemoglobin sigmoid curve shifts to the right
and increases the release of oxygen at the tissue level.
The erythrocytes mop up most of the H2O2 and
promptly reduce it to water by GSH. The sudden forma-
tion of GSSG (oxidized glutathione) alters the GSH/
GSSG ratio but the cell quickly correct it by either
extruding some glutathione-disulphide or by reducing it
via GSH reductase at the expense of either ascorbic acid
or thioredoxin, which has two-SH groups. Moreover,
the activation of glucose-6-phosphate dehydrogenase
(G6PDH) provides reducing power and activate
glycolysis.
ii) in the leukocytes: neutrophil phagocytic activity is
enhanced. Inside monocytes and lymphocytes, H2O2
activates a tyrosin-kinase with consequent phosphoryla-
tion of IkB, one of the trimeric components at rest of
the NF-kB [33,34]. The phosphorylated IkB detaches
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from the trimer and it is broken down in the proteasome.
The remaining eterodimer p50-p65 is transferred into
the nucleus where it can activate about 100 genes. Of
great significance it is the final release of some cytokines
(IFNg and IL-8) and of some acute-phase proteins [11];
iii) in the platelets. In relation to the ozone concentra-
tion, we have measured release of PDGF-AB, TGFb-1
and IL-8 [35]. Growth factors have a specific relevance
in enhancing ulcer’s healing. in peripheral arterial
disease (PAD).
It must be said that the H2O2 concentration in the
cells (4 μM) is essential for switching on cellular
responses and it probably lasts few seconds as GSH-Pxs,
peroxiredoxin and catalase promptly reduce it to H2O.
In plasma, the H2O2 half-life is less than 1 minute and
it is absent during blood reinfusion.
On the other hand, among a variety of LOPs, newly
formed lipoperoxide radicals are rapidly reduced to
hydroperoxide while among a variety of alkenals, the
bulk originated by n-6 polyunsaturated fatty acids
(PUFA) is represented by the fairly stable 4-HNE
(4-Hydroxy-2-nonenal) [36], while 4-HHE is a product
of n-3 PUFA [37,38]. Both aldehydes are amphipathic
molecules reacting with free GSH, carnosine and mainly
albumin. They eventually act as useful messengers and
their toxicity is quenched by three processes schemati-
cally indicated as: a) detoxification, b) dilution, and c)
excretion. Specifically:
a) Small aliquots are broken down at once by enzymes
such as GSH-S-transferases and aldehyde dehydrogenase
or by other detoxifying enzymes described by Awasthi
et al. [39];
b) the bulk is bound to the -SH group of Cys34
present in domain-I of albumin but also to free GSH.
Eleven nucleophilic residues (Lys199 and His146) can
also bind up as many as eleven aldehydic molecules
[40,41]. Moreover, GSH can be oxidized to a sulfonic
acid while the -SH group of albumin may be oxidized to
sulfenic acid [42,43].
Thus, owing to the high albumin amount (about 280 g
in man), the bound alkenals undergo a great dilution in
the body fluids implying a most important loss of toxi-
city. Alkenals have not a membrane receptor but the
albumin adduct can transport it everywhere in the body.
c) Aldehydes are also excreted into bile and urine after
hepatic detoxification [44] and renal excretion as mer-
capturic acid conjugates [45].
An interesting aspect is that albumin can transport
alkenal adducts in all body tissues, from liver to endo-
crine glands and the central nervous system. Thus
4-HNE-Cys adducts can be released at many sites and
inform a variety of cells of a transient, acute oxidative
stress. At submicromolar or picomolar levels, 4-HNE
can act as a well-known signaling molecule [36] able to
activate the synthesis of g-glutamate cysteine ligase,
g-glutamyl transferase, g-glutamyl transpeptidase, HSP-
70, heme-oxygenase-I (HO-1), and antioxidant enzymes
such as superoxide dismutase (SOD), GSH-peroxidase,
catalase and last but not least important, G6PDH, a cri-
tical enzyme electron-donor during erythropoiesis in the
bone marrow. There is a wide consensus on the rele-
vance of the induction of protective molecules during
repeated oxidative stress [46-52] and it is of interest that
these small stresses are of crucial importance for pre-
venting and treating hypertension, stroke and heart
infarction. Indeed in our clinical trial in peripheral arter-
ial disease (PAD) ozonetherapy has proved to be better
than the orthodox infusion of iloprost [53].
Ozone therapy is based upon a real hormetic concept
where the optimal ozone dose must never overwhelm
the potent antioxidant capacity of blood [54,55].
At the time of ozonated blood infusion, 4-HNE-Cys
adduct can also act on the vast expanse of endothelial
cells and, by stimulating the endothelial nitric oxide
synthase (eNOS) enhances the biosynthesis of NO via
the 5-electron oxidation of L-arginine. NO, S-nitro-
sothiols and a trace of CO released with bilirubin via
the upregulation of HO-1 activity allows vasodilation,
thus improving tissue oxygenation in ischemic tissues.
Moreover, an increased production of NO counteracts
the excessive endothelial release of O2
- caused by the
chronic inflammation typical of atherosclerosis. Thus,
both NO and CO released in trace amounts, accomplish
the task of important physiological mediators. Finally,
the majority of patients, undergoing several treatments,
report a feeling of euphoria and a sense of wellness
probably due to an improved hormonal secretion and/or
better utilization of neurotransmitters. Most impor-
tantly, by using the above reported therapeutic range of
ozone concentrations strictly related to the blood
volume, it must be noted that neither acute nor chronic
toxicity has been ever observed during or after ozone
therapy [19].
In conclusion it can be stated that the M-O3-AHT
owing to the precise volume of blood, the precise
volume of ozone of which the exact concentration is
photometrically determined, hence the real dose, makes
it the unsurpassed method because ozone instantly
reacts with several blood substrates in a quantitative and
predictable fashion.
B) Modalities of ozone administration
It is clear that ozone can be administered with great
flexibility but it should never be directly injected as a
gas mixture in the circulatory vessels because of the risk
of provoking oxygen embolism, given the fact that the
gas mixture never contains less than 95% oxygen. Sche-
matically, the methods of ozone administrations can be
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classified as follows. The ozonated autohemotherapy
(O3-AHT), distinguished in: B1) Major (M-O3-AHT),
and B2) minor (m-O3-AHT), in relation to the blood
volume; as well as B3) Extravascular Blood Oxygena-
tion-Ozonation (EBOO). B4) The quasi-total body expo-
sure (QTBE) to O2-O3. B5) The various forms of ozone
administration into different tissues: i) subcutaneous
(SC); ii) intramuscular (IM); iii) intradiscal (ID); iv)
intracavitary (peritoneal and pleural spaces); v) intravagi-
nal, intrauretral and vesical; vi) for dental applications,
mainly as ozonated water. In detail:
B1) In the M-O3-AHT, a predetermined volume of
blood (from 100 up to 225 mL, on the basis of the
patient’s body weight) to which has been added either
sodium citrate 3.8% (1+ 9 mL blood) or heparin (20 IU/
mL of blood) can be exposed to an equal volume of gas
mixture (95%O2-5%O3), with the ozone concentration
(from 20 up to 80 μg/mL of gas per mL of blood, i.e.:
0,42-1,68 mM) precisely determined by using an ozone-
resistant, disposable 500 ml glass bottle under vacuum.
This simple, inexpensive (all the necessary disposable
material costs about 15 US$) procedure has already
yielded therapeutic results in chronic limb ischemia
superior to those achieved by conventional medicine
[53]. It is also useful as a supporting help in chronic
infection diseases and probably in autoimmune
disorders.
B2) The m-O3-AHT is also precise and it consists in
treating usually 5 mL of blood with an equal volume of
gas mixture (O2-O3) with an ozone concentration of 80-
100 mg/L of gas per mL of blood (total ozone dose =
0.4-0.5 mg). In this case the blood is vigorously mixed
with the gas mixture for about 1 min and immediately
injected in the gluteus muscle with the gas foam. It has
different aims because it acts as an immune enhancer
and inducer of heme-oxygenase 1 (HO-1). It is easy to
perform, inexpensive, safe and well-tolerated. It supports
the M-O3-AHT in chronic infection diseases especially
useful in herpetic infections [56].
B3) The EBOO is a procedure to be used in emer-
gency conditions such as PAD stage 4, because of com-
plexity and invasiveness due to blood collection and
infusion from two contralateral veins and blood circula-
tion through an ozone-resistant gas exchanger [57,58].
Finally, by using a peristaltic pump, blood returns to the
circulation via a contra lateral vein. About 5L of blood
can be oxygenated-ozonated within one hour during
which the blood/ozone quantities can be varied but
always precisely determined. It has a precise rationale
and normally procures a rapid improvement. However,
it is expensive and must be performed by technicians
specialized in extravascular blood circulation [57].
B4) The QTBE to O2-O3 for avoiding the inhalation
of ozone exclude the head and the neck of the patient.
On the other hand, the extensive cutaneous exposure
to O2-O3 does not need any venous puncture and,
owing to the vast expanse of the skin (about 1.5 m2)
allows a generalized and beneficial effect. The usual
exposure time in a perfectly insulated ozone-resistant
cabinet is 20-30 min: the final ozone concentration
during treatment is below 1 μg/mL delivered at both
controlled and modifiable temperature (37-40°C) and
Relative Humidity (≤100%) depending upon the pathol-
ogy and the state of the patient. Ozone, while is never
absorbed as such through the skin because it always
reacts with the aqueous-lipidic cutaneous surface,
allows the well-demonstrated absorption of LOPs [59].
There is no doubt that it has a pharmacological effect
that, although less predictable than M-O3-AHT, exerts
beneficial effects in cardiovascular, infectious diseases
and in aging [60].
B5) Administration of ozone into different tissues
i) In the past, O2-O3 mixture was injected into subcuta-
neous tissue. The ozone concentration should never
exceed 20 μg/mL and the gas volume 20 mL because it
elicits a transient pain and the risk of embolism must be
avoided. Total multiple injections (up to 50) of 1 mL
each with an ozone concentration of 2-3 μg/mL are per-
formed as a therapy for lipodistrophy [61].
ii) Monolateral or even bilateral injection of 5-10 mL
of gas with an ozone concentration of up to 20 μg/mL
is performed into the trigger points of the paravertebral
muscles corresponding to the metamers of the herniated
disc usually interesting from L4 to S1 [62]. This “chemi-
cal acupuncture” is the indirect approach for treating
lumbar disc herniation and alternate daily treatments
for about 3 weeks yield a therapeutic results in about
68% of the patients [63]. Otherwise,
iii) The injection of gas (2-5 mL) with an ozone con-
centration of 30 μg/mL is directly performed into the
herniated nucleus pulposus under radioscopic control.
The percentage of cure is almost 80% [64-66];
iv) In the case of mesothelioma, peritoneal carcinoma-
tosis or peritonitis, endoperitoneal or endopleural injec-
tion of up to 2500 mL of gaseous mixture with an
ozone concentration of 10-20 μg/mL can be performed.
This modality is rarely used in Western Countries and
must be performed by a specialist [Bocci V, Zanardi I,
Travagli V: A rational innovative treatment for peri-
toneal carcinomatosis. Cancer Invest. 2011, submitted];
v) Insufflation of variable volumes of gas (50-200 mL)
with an ozone concentration ranging between 10-15
μg/mL of gas can be done into the vaginal, uretral and
vesical cavity for different types of infections or in the case
of post-radiation microhemorrhage of the bladder [67].
Vaginal washing with ozonated water (20 μg/mL) and
ozonated oil pessaries are very efficacious;
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vi) Primary root carious lesions are successfully
treated in children by using a dental handpiece with a
removable silicon cup for exposing the tooth’s lesion to
the gas without any leakage [68].
To summarize, ozone is characterized by versatility and
the various modalities for its administration have been
described. As for the clinical application, ozonated
autohemotherapy is specifically suited to treat vascular
diseases (e.g. stroke, peripheral arterial as well as chronic
heart disease) associated with some age-degeneration
(macular degeneration, dry form). It can be as a useful
supportive therapy in chronic infectious diseases,
diabetes and cancer, but it is not curative. On the other
hand, cutaneous and ulcerative infections are excellently
treated with topical application of ozonated oils and
ozonated water. Such derivatives have been also used in
dentistry (primary carious lesions). Finally, gaseous oxy-
gen-ozone mixture is remarkably important in orthopedy
(herniated disk).
All of these modalities, if performed by skilled hands,
are very effective and practically risk-free.
Are other modalities of ozone administration safe and
effective?
It is indispensable to discuss this problem because of
the spreading of methodologies by inexpert and impro-
vised ozone therapists, possibly non-physicians, can dee-
ply damage patients and compromise the future of
ozone therapy. It has become known that during the
early 90’s, technicians migrated into Africa and Antilles,
performed direct intravenous injections of gas for treat-
ing HIV infections in desperate patients. In spite of a
slow infusion, several cases of embolism and deaths
have occurred. It is deplorable that even today in
Western countries, certain physicians are still using this
technique officially forbidden in Europe since 1984.
They believe that ozone directly infused into the venous
system is more effective because they do not know that
ozone immediately dissolves into the plasmatic water
and, owing to necessarily minute quantities, is mostly
neutralized by the wealth of antioxidants. Furthermore,
both intracellular and free viruses are well protected by
the antioxidant system. On the other hand, the bulk of
oxygen, far less soluble than ozone, forms bubbles
leading to lung embolism.
However, the actual problem must be focused on the
infusion of ozonated saline [69]. Although nobody can
criticize the M-O3-AHT where equal volumes of gas
and blood are precisely regulated, it must be admitted
that the blood withdrawal phase, by using a G19 needle,
takes about 10 minutes. As a consequence, the further 5
min mixing and about 20 min infusion into the donor
imply a time period not available in hospitals where
thousands of patients have to be treated every day.
Indeed, since 1994 the need of a valid blood substitute
was felt necessary and after an extensive search, we
found that the simple physiological saline (NaCl 0.9%)
could represent a possible pharmaceutical vehicle. After
testing a variety of ozone concentrations, it was found
that bubbling in saline gaseous mixture with an ozone
concentration of 70 μg/mL for 10 min in saline could
produce a level of H2O2 therapeutically acceptable.
However, after the infusion of this solution in ourselves,
it was experienced a painful feeling along the venous
route in the infused arm during the next 24 h likely due
to endothelial inflammation. A further checking revealed
the transient presence of HClO as the most likely offen-
sive agent, although Razumovskii et al., by using far
lower O3 concentration have not detected hypochlorite
[70,71].
It was immediately obvious that the idea of ozonated
saline had to be abandoned. However, at about the same
time Russian clinicians decided that by ozonating saline
with an ozone concentration as low as 2-3 μg/mL could
be a viable and very quick solution to prepare and
infuse every day a multitude of patients. Although it had
been claimed that infusion of ozonated saline had a
similar beneficial effect of M-O3-AHT, to the best of
our knowledge no comparative clinical studies has
appeared in the international literature during the last
15 years. At a recent Congress of Ozone Therapy held
in Instanbul, Dr. E.I. Nazarov, President of the Ukraine
Association of Ozone therapy confirmed that in Russia
and Ukraine the Ministry of Health had recommended
that the concentration of ozone in saline solution should
not exceed 3 mg/L [69]. Consequently, Dr. Nazarov has
developed a device (Bozon-N) able to automatically
measure the ozone concentration in saline, establishing
and supporting the same ozone concentration during
the infusion. This suggests that if ozone is always pre-
sent, hypochlorous acid even if in trace amount, will be
also continuously generated. Although it is an excellent
bactericidal compound - also produced by phagocytic
cell mieloperoxidase - it exerts a deleterious reactivity
with protein -SH groups, amino groups (chloramines
formation) with DNA, RNA, and lipids. Moreover, ClO-
is one of the most noxious ROS during the chronic
inflammation accompanying several pathologies.
As the infusion of ozonated saline is very cheap, mini-
mal time-consuming than M-O3-AHT and quite remu-
nerative for the practitioners, physicians have started to
use it also in several Western countries and it is foresee-
able that it will be extensively used in poor countries,
possibly at higher ozone concentrations. Indeed, Ikono-
midis et al. have reported that they maintain the saline
solution under a constant flow of O3 during IV infusion
but they warned that the maximum amount of O3 daily
administered is usually 4-5 mg and should never exceed
8-10 mg [72]. In their publication they also stated “if we
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exceed these rates, the over coagulation syndrome
starts” and they strongly recommend to perform coagu-
lation tests before starting therapy. These warnings
reinforce our preliminary objection to this approach.
Moreover Foksinski et al. have detected 8-oxodeoxygua-
nosine, a typical oxidative DNA damage in lymphocytes
of atherosclerotic patients after the IV infusion of ozo-
nated saline, that is a worrisome result never detected
after M-O3-AHT [73].
Fortunately, to the best of our knowledge, Russian
physicians ozonize the saline with very low O3 concen-
trations (2-3 μg/mL) and this precaution certainly mini-
mizes toxicity but it leaves open the aspect of
therapeutic efficacy. At the infusion time, 250 mL of
saline may contain about 0.5 mg of ozone, which will be
entirely neutralized by antioxidants. On average M-O3-
AHT receives about 10 mg of ozone and it is pharmaco-
logically effective. Moreover, ozonation of saline is
clearly an unstable process and therefore dangerous pre-
paration because a pharmaco-therapeutic principle has
long established on the basis of the exact knowledge of
the constituents and their stability.
It is therefore necessary to enumerate and discuss the
problems occurring during the preparation of ozonated
saline:
1) For human use it would be unwise to use O3 con-
centration over 3 μg/mL (3 mg/L). Moreover it is essen-
tial to establish the volume per minute of the gas
mixture O2-O3. The big problem is that different ozone
generators present in the market have variable gas out-
put: if it is 1 L per minute, the O3 delivered to 200 mL
of saline would be 3 mg/L but, if the output per minute
is equivalent to 3 litres of gas, then the actual dose of
O3 delivered will be 9 mg/L! Not to mention the risk of
using more than 3 μg/mL of ozone. As a consequence
one must properly warn the ozone therapist in relation
to the owned ozone generator as otherwise one risks to
poison the patient.
2) The period of ozonation time also ought to be well
defined in relation to the volume of saline because in
the case of saline solution an ozonation time of 20 min
appears enough to reach a plateau. Obviously a shorter
or longer ozonation period will differently modify the
concentration of hydrogen peroxide, O3 and other
radicals.
3) Another aspect to be clearly defined if gas bubbling
will continue or not during the IV infusion period. This
is because, as soon as the gas bubbling is stopped, the
concentration of H2O2 remains fairly stable but the O3
concentration will halve during the next 30 min and
this affects the therapeutic result. As a trivial example, it
is doubtful that in a large clinic all the saline infusions
are all under a continuous O3 bubbling and it is likely
that saline bottles will be ozonated and then distributed
implying a more or less long delay before the infusion.
After one hour delay, O3 is not longer present.
As a preliminary conclusion, one must seriously
ponder on the validity of using the infusion of ozonated
saline. It is certainly less dangerous than the direct IV
infusion of the gas mixture that some doctors still dare
to perform. However, it does not represent an improve-
ment because the variable presence of H2O2, O3, and
similar, does not insure neither a good reproducibility,
nor a consistent therapeutic effect. Moreover the blood
flow in the cubital vein varies considerably in different
patients and in women. Consequently, a fairly constant
infusion of ozonated saline versus a variable blood
content of antioxidants implies an uncertain blood/
H2O2-O3 relationship with possibly a too low or too
high bio-oxidation. By comparison, a fundamental pillar
of the classical M-O3-AHT is that we can maintain pre-
cisely the blood/O3 ratio within the known therapeutic
range. In summary, the ozonated saline approach con-
tains too many uncertain parameters and, in any case, it
needs to be carefully standardized to avoid the risk of a
placebo infusion or an excessive and risky treatment.
Nonetheless if, on the basis of the critical need to treat
too many patients, it is allowed by Russian Health
Authorities, it will be never accepted by neither the
FDA, USA or by the EU Health Authorities. Thus, in
spite of recent studies which exclude the toxic danger of
ClO- formation by using no more than 3 mg/L of ozone
[70,71], the use of ozonated saline remains a constant
danger.
Another irrational procedure called Celacade (pro-
moted by Vasogen Inc., Canada) consisted in exposing
10 mL of human blood to an oxygen/ozone gas mixture
(ozone concentration 15.35 g/m3) delivered into the
blood at a flow of 240 mL/min and UV light (253.7 nm)
at a temperature of 42.5°C for about 20 min. The trea-
ted blood sample was removed from the system and
immediately administered by intragluteal injection to the
donor patient. Two treatments were given on consecu-
tive days, followed by a third on day 14. Subsequent
treatments were given at 4 week (28 days) intervals for
at least 22 weeks, for a total of 8 injections.
The procedure used an expensive device able to deli-
ver an enormously toxic dose of ozone (107.5 mg per
mL of blood) plus an undetermined UV irradiation at
42.5°C. The final ozone dose is about 15000-fold higher
than the average ozone dose used during the classical
O3-AHT and the extremely high oxidation of blood
causes a complete denaturation of blood components.
This procedure was invented aiming to establish a non-
specific immunomodulation therapy (IMT) in the hope
of reducing the inflammatory process and the chronic
oxidative stress present in vascular diseases. It has
proved to be useless in a multicenter, randomized,
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double-blind, placebo-controlled study in 533 patients
with symptomatic peripheral arterial disease (PAD),
called the SIMPADICO trial [74]. It is most important
noting that this trial had to be stopped three months
early because it did not show any improvement in PAD
and caused a significantly higher rate of malignancies in
the IMT group [75]. Moreover, a subsequent multicen-
ter study in 2426 patients, called the ACCLAIM trial, in
chronic heart failure resulted in a “disappointing” results
[76]. Thus almost 3000 patients with critical vascular
pathologies have undergone a useless and potentially
dangerous procedure. Moreover, in spite of two com-
mentaries reprimanding the EMA [77,78], it seems that
the ozone-UV-heat apparatus remains on sale in Europe.
Another route of administration of ozone, firstly
advocated by Dr. Aubourg is the insufflations of O2-O3
gaseous mixture into the rectum for treating chronic
colitis and fistulae [79]. In 1936 this was a reasonable
application which it has been now extended to treat all
diseases. The insufflations of a volume of 200-300 mL of
gas into the rectum-colon at ozone concentration ran-
ging from 5 to no more than 35 μg/mL can be precisely
done but it remains unpredictable as an effective dose
of ozone because of a possible flatulence and the pre-
sence of a more or less abundant luminal content. Thus,
it is obvious to predict that a significant fraction of the
dose will be neutralized by fecal material. The residual
dose of ozone will dissolve and be neutralized into the
layer composed of glycocalix and mucoproteins covering
the mucosa. Ozone will instantly and fully react with
these compounds but only a LOPs fraction will be
absorbed with O2 by the mucosa. Indeed, in a rabbit
experiment we have shown a transient presence of
LOPs in the portal vein [80], but obviously the real
pharmacological effect on vascular diseases and diabetes
remains uncertain.
Once again, while in Western countries many patients
object to this route, at Cuba they have thousands of
patients to be treated every day and they have adopted
this rapid, inexpensive procedure in all patients always
administering 200 mL of gaseous O2-O3 mixture with
the excessive ozone concentration of 50 μg/mL (ozone
dose: 10 mg). Firstly, the ozone concentration is too
high and during prolonged use may be mutagenic;
secondly, this route, being so uncertain, should not be
used in controlled clinical trials. Indeed, it seems that in
only twenty days that dosage could cure (?) the diabetic
foot in a number of patients treated with rectal ozone
and topical ozonated oil [81].
Finally, owing to the fact that H2O2 is one of the most
important ROS generated by O3, since 2005 [82], in
women with very difficult venous access, by using a G27
needle, we have intravenously infused the solution of
pure H2O2 in glucose (5%) or saline solutions at the
concentrations ranging from 0.03-0.06% (8-16 mM).
The bio-oxidative therapy with H2O2 was first described
by Dr. I.N. Love in 1888 [83] and then promoted by
Dr. C.H. Farr in 1993 [84]. We showed a modest but
consistent activity in women with age-related macular
degeneration. In contrast to ozonated saline, this com-
promise, very simple to prepare, does not contain other
dangerous ROS and moreover there is no need for
ozone generators. This solution has the further advan-
tage to be possibly used in remote African and Asian
areas. Obviously, the glucose solution should not be
used in diabetic patients but H2O2 can be dissolved in
physiological solution and used at once.
Conclusions and perspectives
The application of ozone in medicine represents one of
the most intriguing adventures in research. First of all
because ozone is too well known as a toxic gas in the
troposphere and secondly, in spite of courageous pio-
neers like Payr, Fisch, Wolff and Auborg, ozone stalled
in an empirical phase for almost three decades and it
was heavily damaged by the improper use of direct IV
infusion by so-called doctors in desperate HIV-AIDS
patients. This dangerous and useless application, asso-
ciated with other deplorable episodes, led the FDA to
prohibit the use of ozone in medicine. Today, the basic
mechanisms of action of ozone in blood, documenting
the existence of a therapeutic window and establishing a
framework for understanding and recommending ozone
therapy in some diseases have been clarified and we can
start to see a faint light at the end of the tunnel. How-
ever, owing to the lack of sponsors and funding, the
clinical work, fundamental for demonstrating the validity
of ozone therapy, proceeds at a snail pace. Furthermore,
the urgent need of treating too many patients in poor
countries has stimulated the use of “cheap and quick”
procedures that hinder progress. Clinical scientists for
either prejudice, or lack of knowledge, or exclusive
interest in pharmaceutical drugs disregard, if not object,
ozone therapy that remains in the hands of practitioners
who cannot deliver reliable scientific reports. Thus, opti-
mistically let us say that we are at the end of the begin-
ning but our enthusiasm remains high and we will
continue our efforts for allowing the acceptance of
ozone therapy as an efficacious approach to be included
among the armamentarium of orthodox medicine.
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